An unprecedented global pandemic caused by a novel coronavirus named SARS-CoV-2
has created a severe healthcare threat and become one of the biggest challenges to human …

This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …

Introduction There are currently some differences in the research results of molnupiravir.
This study aimed to evaluate the efficacy and safety of molnupiravir in the treatment of …

The aim of this meta-analysis is to evaluate the efficacy of molnupiravir among mild or
moderate COVID-19 patients. This meta-analysis was reported according to the guidelines …

Molnupiravir is an antiviral drug against viral RNA polymerase activity approved by the FDA
for the treatment of COVID-19, which is metabolized to β-D-N4-hydroxycytidine (NHC) in …

Introduction COVID-19 is caused by infection with the severe acute respiratory syndrome
coronavirus type 2 (SARS-CoV-2). As the respiratory tract is the primary site of infection and …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), characterized by its high
fatality rate and contagious nature, has led to significant morbidity and mortality worldwide …

Abstract Molnupiravir (EIDD-2801)(MLN) is an oral antiviral drug for COVID-19 treatment,
being integrated into viral RNA through RNA-dependent RNA polymerase (RdRp). Upon …

Introduction: The coronavirus disease 2019 (COVID-19) pandemic started in March 2020.
Since then, there has been an urgent need for effective therapeutic methods to manage the …

Objective To assess the real-world effectiveness of molnupiravir (MOL) in reducing the need
for hospitalization in at-risk, non-hospitalized patients with confirmed COVID-19. Methods A …